Lude Franke
Auto-generated profile, based on publicly available information

Lude Franke

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2014 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CGClaudia Giambartolomei
Claudia Giambartolomei
DVDamjan Vukcevic
Damjan Vukcevic
ESEric E Schadt
Eric E Schadt
LFLude Franke
Lude Franke
AHAroon D Hingorani
Aroon D Hingorani
VPVincent Plagnol
Vincent Plagnol
Genetic association studies, in particular the genome-wide association study (GWAS) design, have provided a wealth of novel insights into the aetiology of a wide range of human diseases and traits, in particular cardiovascular diseases and lipid biomarkers. The next challenge consists of understanding the molecular basis of these associations. The integration of multiple association datasets, including gene expression datasets, can contribute to this goal. We have developed a novel statistical methodology to assess whether two association signals are consistent with a shared causal variant. An application is the integration of disease scans with expression quantitative trait locus (eQTL) studies, but any pair of GWAS datasets can be integrated in this framework. We demonstrate the value of the approach by re-analysing a gene expression dataset in 966 liver samples with a published meta-analysis of lipid traits including >100,000 individuals of European ancestry. Combining all lipid biomarkers, our re-analysis supported 26 out of 38 reported colocalisation results with eQTLs and identified 14 new colocalisation results, hence highlighting the value of a formal statistical test. In three cases of reported eQTL-lipid pairs (SYPL2, IFT172, TBKBP1) for which our analysis suggests that the eQTL pattern is not consistent with the lipid association, we identify alternative colocalisation results with SORT1, GCKR, and KPNB1, indicating that these genes are more likely to be causal in these genomic intervals. A key feature of the method is the ability to derive the output statistics from single SNP summary statistics, hence making it possible to perform systematic meta-analysis type comparisons across multiple GWAS datasets (implemented online at http://coloc.cs.ucl.ac.uk/coloc/). Our methodology provides information about candidate causal genes in associated intervals and has direct implications for the understanding of complex diseases as well as the design of drugs to target disease pathways. Genome-wide association studies (GWAS) have found a large number of genetic regions (“loci”) affecting clinical end-points and phenotypes, many outside coding intervals. One approach to understanding the biological basis of these associations has been to explore whether GWAS signals from intermediate cellular phenotypes, in particular gene expression, are located in the same loci (“colocalise”) and are potentially mediating the disease signals. However, it is not clear how to assess whether the same variants are responsible for the two GWAS signals or whether it is distinct causal variants close to each other. In this paper, we describe a statistical method that can use simply single variant summary statistics to test for colocalisation of GWAS signals. We describe one application of our method to a meta-analysis of blood lipids and liver expression, although any two datasets resulting from association studies can be used. Our method is able to detect the subset of GWAS signals explained by regulatory effects and identify candidate genes affected by the same GWAS variants. As summary GWAS data are increasingly available, applications of colocalisation methods to integrate the findings will be essential for functional follow-up, and will also be particularly useful to identify tissue specific signals in eQTL datasets.

20 July 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JLJimmy Z Liu
Jimmy Z Liu
SSSuzanne van Sommeren
Suzanne van Sommeren
HHHailiang Huang
Hailiang Huang
SNSiew C Ng
Siew C Ng
RARudi Alberts
Rudi Alberts
RWRinse K Weersma
Rinse K Weersma

2 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
UVUrmo Võsa
Urmo Võsa
ACAnnique Claringbould
Annique Claringbould
HWHarm-Jan Westra
Harm-Jan Westra
MBMarc Jan Bonder
Marc Jan Bonder
PDPatrick Deelen
Patrick Deelen
LFLude Franke
Lude Franke

25 December 2013 in Nature
Verified
Journal Article
Open access
PDF file
TCthe RACI consortium
the RACI consortium
YOYukinori Okada
Yukinori Okada
TCthe GARNET consortium
the GARNET consortium
DWDi Wu
Di Wu
GTGosia Trynka
Gosia Trynka
RPRobert M. Plenge
Robert M. Plenge
A genome-wide association study meta-analysis of more than 100,000 subjects of European and Asian ancestries reveals 42 new risk loci for rheumatoid arthritis, with follow-up studies identifying 98 biological candidate genes that are either already being targeted by drugs or could be in the future. Virtual screening in a genome-wide association study (GWAS) meta-analysis of more than 100,000 subjects of European and Asian ancestries has revealed 42 previously unknown risk loci for rheumatoid arthritis (RA). As a follow-up, the authors developed a new in silico pipeline to identify 98 biological candidate genes at all known RA risk loci. They show that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological data sets to provide insight into disease pathogenesis and guide drug discovery for complex traits such as rheumatoid arthritis (RA)1. Here we performed a genome-wide association study meta-analysis in a total of >100,000 subjects of European and Asian ancestries (29,880 RA cases and 73,758 controls), by evaluating ∼10 million single-nucleotide polymorphisms. We discovered 42 novel RA risk loci at a genome-wide level of significance, bringing the total to 101 (refs 2, 3, 4). We devised an in silico pipeline using established bioinformatics methods based on functional annotation5, cis-acting expression quantitative trait loci6 and pathway analyses7,8,9—as well as novel methods based on genetic overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mouse phenotypes—to identify 98 biological candidate genes at these 101 risk loci. We demonstrate that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. Together, this comprehensive genetic study sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis, and provides empirical evidence that the genetics of RA can provide important information for drug discovery.

5 October 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe Electronic Medical Records and Genomics (eMERGE) Consortium
The Electronic Medical Records and Genomics (eMERGE) Consortium
AWAndrew R Wood
Andrew R Wood
TCThe MIGen Consortium
The MIGen Consortium
TCThe PAGE Consortium
The PAGE Consortium
TSThe LifeLines Cohort Study
The LifeLines Cohort Study
TFTimothy M Frayling
Timothy M Frayling
Timothy Frayling, Joel Hirschhorn, Peter Visscher and colleagues report a meta-analysis of genome-wide association studies for adult height in 253,288 individuals. They identify 697 variants in 423 loci significantly associated with adult height and find that these variants cluster in pathways involved in growth and together explain one-fifth of the heritability for this trait. Using genome-wide data from 253,288 individuals, we identified 697 variants at genome-wide significance that together explained one-fifth of the heritability for adult height. By testing different numbers of variants in independent studies, we show that the most strongly associated ∼2,000, ∼3,700 and ∼9,500 SNPs explained ∼21%, ∼24% and ∼29% of phenotypic variance. Furthermore, all common variants together captured 60% of heritability. The 697 variants clustered in 423 loci were enriched for genes, pathways and tissue types known to be involved in growth and together implicated genes and pathways not highlighted in earlier efforts, such as signaling by fibroblast growth factors, WNT/β-catenin and chondroitin sulfate–related genes. We identified several genes and pathways not previously connected with human skeletal growth, including mTOR, osteoglycin and binding of hyaluronic acid. Our results indicate a genetic architecture for human height that is characterized by a very large but finite number (thousands) of causal variants.

29 April 2016 in Science
Verified
Journal Article
Closed access
PDF file
AZAlexandra Zhernakova
Alexandra Zhernakova
AKAlexander Kurilshikov
Alexander Kurilshikov
MBMarc Jan Bonder
Marc Jan Bonder
ETEttje F. Tigchelaar
Ettje F. Tigchelaar
MSMelanie Schirmer
Melanie Schirmer
JFJing Fu
Jing Fu
“Normal” for the gut microbiota: For the benefit of future clinical studies, it is critical to establish what constitutes a “normal” gut microbiome, if it exists at all. Through fecal samples and questionnaires, Falony et al. and Zhernakova et al. targeted general populations in Belgium and the Netherlands, respectively. Gut microbiota composition correlated with a range of factors including diet, use of medication, red blood cell counts, fecal chromogranin A, and stool consistency. The data give some hints for possible biomarkers of normal gut communities. Science , this issue pp. 560 and 565